

**For Immediate Release**TSX Exchange Symbol: **RVX****MEDIA AWARENESS ANNOUNCEMENT****Resverlogix Corp. NexVas™ Education Program****Wins Prestigious International Telly Award**

CALGARY, AB, April 28, 2006 – Resverlogix Corp. (TSX: RVX), is pleased to announce that its NexVas™ animation has won the prestigious international Telly Bronze Award for the Use of Animation Category.

The Telly Awards honor outstanding local, regional, and cable television commercials and programs, as well as the finest video and film productions. Since 1978, the mission of the Telly awards has been to strengthen the visual arts community by inspiring, promoting, and supporting creativity. The 27th Annual Telly Awards received over 12,000 entries from all 50 states and 5 continents. Today, the Telly is one of the most sought-after awards by industry leaders, from large international firms to local production companies and ad agencies.

The NexVas™ animation was co-developed by Resverlogix and InViVo Communications Inc., a leading Canadian healthcare new media company. The complete animation is available for viewing and can be accessed at Resverlogix's website [www.resverlogix.com/nexvas.htm](http://www.resverlogix.com/nexvas.htm). The main purpose of the animation is to educate all key stakeholders in cardiovascular disease management about the importance of ApoA-I and its role in reducing the main underlying cause of CVD, atherosclerosis.

“Winning this prestigious award for our NexVas™ animation is important for us as it validates our intent of building effective communication vehicles for all of our key stakeholders on our technologies,” stated Donald McCaffrey, President and CEO of Resverlogix. “The NexVas™ animation has been the number one page viewed on our website month after month. We trust that individuals who view the animation will now have a better understanding of how NexVas™ ApoA-I enhancement technology works and its promising potential in CVD.”

“A core part of our corporate strategy is to educate and inform patients, investors and the life sciences community on the importance of NexVas™ as an emerging therapy for reducing the grievous burden of CVD,” stated Kenneth Lebioda, Vice President of Business and Market Development of Resverlogix. “We are very happy we planned and built this communication platform with a leading medical animation company such as InViVo to illustrate the important cardio-protective role of ApoA-I in reducing atherosclerosis and also how our company is well positioned in this very important life science market where a major unmet need still exists.”

## **About Resverlogix Corp.**

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's lead technology NexVas™, applies advanced medical research to develop therapies that increase ApoA-I the key protein of high density lipoprotein (HDL), the "good cholesterol," and other targets to treat cardiovascular diseases (CVD). The Company's second CVD research program ReVas™ is dedicated to developing novel compounds for acute based drug therapy via a medical device.

Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: [www.resverlogix.com](http://www.resverlogix.com).

*This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not except responsibility for the adequacy or accuracy of this news release.*

### **For further information please contact:**

**Donald J. McCaffrey**

President/CEO

Resverlogix Corp.

Phone: 403-254-9252 ext. 223

Fax: 403-256-8495

[don@resverlogix.com](mailto:don@resverlogix.com)

**Kenneth Lebioda**

VP Business & Market Development

Resverlogix Corp.

Phone: 403-254-9252 ext. 227

Fax: 403-256-8495

[ken@resverlogix.com](mailto:ken@resverlogix.com)